Pune, Sept. 24

Prejex has entered into an agreement with Polybond, headed by Mr.AditRathi of the Rathi Group, to manufacture needle-less injections. This partnership has enabled the shifting of the manufacturing capabilities of the German company from Berlin to Pune. The Prejex-Polybond factory will make needleless injections for the entire world.

The efforts of Mr.NirajKhinvasara, CIO, World Trade Center, Pune,and Mr.SagarChordia,Co-Founder and Chairman, The World Trade Hub, Pune,of the World Trade Center, Pune, presented to Prejex ‘Why India & Why Pune?’ A data-based analysis which figured Pune being host to an excess of over 250 German firms was highlighted. The presentation focused on the decision of Mr. Maarten Stuut, MD of Prejex GMBH, and Mr. Harold Gerrits, Director of Global Sales and Distribution, to select India—especially Pune—as their preferred destination.

This influx of FDI is a massive boost for the industrial capacity of Pune. Considering the healthy medical ecosystem in India, it is a win-win situation for all the parties involved. World-class manufacturing units and a long experience in medical manufacturing via its subsidy company, Eversure, made Mr.Rathi the perfect partner for this revolutionary venture.

Prejex: Revolutionary product that the world was waiting for

This new drug delivery system via needle-less injections is a cutting-edge innovation that the medical world has been waiting for quite some time. It provides a solution to a variety of issues that professionals face in day-to-day operations. Syringes and disposable needles are major contributors to toxic waste and their disposal cost is sky-rocketing. Trypanophobia (or the fear of needles) is a common factor leading to the reluctance of patients in drawing of blood and receiving vaccines or intravenous fluids.

With Prejex’s entry, the pain factor is eliminated as the medicine is delivered subcutaneously through the skin which is a reproducible and reliable system. It also negates cross-contamination, ensuring the highest levels of safety and hygiene for doctors and patients alike. Being easy to use, even the caretaker or the patient, themselves, can self-inject reducing visits to the clinic and making healthcare more cost-efficient. It is also highly convenient for customized doses and application of a variety of drugs. The shelf life of the drugs is considerably increased, as well, due to the novel COC polymer syringes and plasticizer. Besides, it will drastically cut down on the use of disposable syringes, most of which are used by diabetic patients, thus adding to the sustainability factor (about 5.5% of the global population, or 422 million people, is diabetic).

 Owing to this New Drug Delivery System or NDDS, medication margins / revenue can be revolutionized. Innovations in supply chain and delivery system hold the potential of making Prejex a pharmaceutical company, as well.

Two different models to be launched

  1. The N-Jector Series, a single-dose disposable device. The dose is ‘pre-charged’ or ‘pre-filled’ in an ampoule and the device can easily be bagged and disposed of once the dose has been administered. The device and / or ampoule can both be stored in a refrigerator or at room temperature.
  2. The Prejex-Multi-Re-Usable Device goes up to 30,000 clicks and is ideal for home use and / or self-administration. It is compatible with pre-filled and non-filled ampoules, which can be attached easily via a simple twist.

A broad spectrum of applications can be covered using these needle-less injections, such as:

  • Diabetes: Insulin and glucagon (antidote to insulin)
  • Endocrinology: Human growth hormone, octreotide etc.
  • Oncology Supportive Care: EPO and G-CSF (Filgrastim)
  • Local Anaesthetics: Lidocaine, dental etc.
  • Autoimmune Diseases: MTX, Humira, Remicade, Enbrel etc.
  • Fertility Hormones: FSH, LH and HCG
  • Erectile Dysfunction: Alprostadil, Trimix
  • Vaccines: HBV, HPV, Flu, MMR etc.
  • Cosmetics: Collagen, Hyaluronic Acid (HA) etc.
  • Biosimilar: beta-IFN, Copaxone, IL-2, Herceptin and many others given subcutaneously

The introduction of needle-less injections is bound to cause a reform in the delivery system of drugs in the near future. The combined efforts of Prejex, the Rathi Group and WTC will be of huge help to the medical industry worldwide.

‘Companies like Prejex can alleviate pain  and make life much easier for patients’

‘Nearly 5% of the World is diabetic i.e. roughly 4.5-5 million people take 2 injections a day and it is companies like Prejex, that can alleviate pain and make life easier for patients. The medical sector is a critical segment for us and companies like Prejex (Needleless Injections) which is a very cutting-edge, innovative and strategic initiative that we are bringing to Pune, by creating and fostering an eco-system of medical innovation in India where we are sourcing distributors too’.

—NirajKhinvasara, CIO, World Trade Center, Pune

For more details contact:


Business Development Manager

World Trade Center, Pune

Mob: +91 9922953414

Website: www.wtc-pune.org

More Press & News